Drug profile · INN
patisiran
ONPATTRO
patisiran (ONPATTRO) is a transthyretin mrna rnai inhibitor. Associated with Lacuna Pharma Pty Ltd.
EMA: approved TGA: approved Nervous system (N07) N07
Patents linked 0
Pipeline programs 10
News articles 0
Drug details — patisiran
- Class
- Nervous system (N07)
- Route
- —
- Patents
- 0
- Programs
- 10
- Data quality
- 0.89
Quick answer
patisiran (ONPATTRO) is a transthyretin mrna rnai inhibitor. Associated with Lacuna Pharma Pty Ltd.
Key facts
INN patisiran
Brand ONPATTRO
Mechanism Transthyretin mRNA RNAi inhibitor
Target Transthyretin mRNA
Therapeutic class Nervous system (N07)
ATC code N07
Originator Lacuna Pharma Pty Ltd
Mechanism of action
Transthyretin mRNA RNAi inhibitor
Primary target: Transthyretin mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is patisiran?
patisiran (ONPATTRO) is a transthyretin mrna rnai inhibitor. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for patisiran?
ONPATTRO is a marketed brand name for patisiran. Check FDA Drugs@FDA for the current US label holder and prescribing information.